Cardamonin as a potential anticancer agent: Preclinical insights and clinical implications

Area of Science:

• Natural Products Chemistry
• Pharmacology
• Oncology

Background:

• Cardamonin, a natural chalcone, exhibits significant anticancer properties in preclinical studies.
• A gap exists between laboratory findings and clinical application due to unresolved translational challenges.

Purpose of the Study:

• To evaluate cardamonin's readiness for clinical trials as an anticancer agent.
• To identify scientific evidence and translational hurdles for cardamonin's anticancer application.

Main Methods:

• Review of preclinical pharmacokinetic, pharmacodynamic, and molecular target data.
• Assessment of cardamonin's antiproliferative, anti-metastatic, and chemosensitizing effects.
• Analysis of signaling pathways inhibited by cardamonin.

Main Results:

• Poor oral bioavailability limits cardamonin's therapeutic potential.
• Cardamonin inhibits key cancer-related signaling pathways (NF-κB, mTOR, STAT3, Wnt/β-catenin).
• Demonstrated antiproliferative, anti-metastatic, and chemosensitizing effects against breast, colorectal, and ovarian cancers.

Conclusions:

• Further research, including in vivo toxicity studies, is needed to assess cardamonin's safety and efficacy.
• Combination therapy with standard chemotherapeutics may enhance cardamonin's clinical applicability.
• Addressing bioavailability issues is crucial for advancing cardamonin into clinical trials.